The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000594325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
13/04/2026
Date registered
Help: Date registered
12/05/2026
Date last updated
Help: Date last updated
12/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
12/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A clinical safety trial evaluating an amended shortened version of the apomorphine pen initiation recommendations in people with Parkinson's disease.
Scientific title
Safety study to evaluate time to ON state with streamlined Apomorphine PEN initiation in patients with Parkinson’s disease.
Additional trial identifiers [1] 317011 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Parkinson's disease 341508 0
Condition category
Condition code
Neurological 337586 337586 0 0
Parkinson's disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This study removes potentially unnecessary steps identified in the current initiation recommendations approved by the Therapeutics Good Administration for the commencement of Apomorphine injections therapy in people with Parkinson's disease (PD). People with PD who experience no nausea with current PD medications and experience significant OFF periods will be injected subcutaneously by our advanced care nurse, with a test dose of 2mg of Apomorphine and assessed for any adverse side effects. Slow, individualized up-titration monitored by our advanced care nurse to optimize tolerability and minimize adverse effects will be done weekly via telehealth. Each participant will document their apomorphine response in a recording table along with any adverse events, which will be reviewed at each telehealth appointment to determine if an increase in dose is required until peak response is reached within one month of commencement. The maximum dose during the up-titration process will be 5mg. The number of injections administered is recorded in the response recording table and is dependent on the number of OFF periods experienced by each individual. The injections are used to treat refractory OFF periods when oral medications are not working traditionally. A minimum of one hour between apomorphine doses is required and no more than 5 doses within a 24-hour period. Peak response is defined as turning the person to "ON" state within 12 minutes with the effect lasting at least 45 minutes. Once the therapeutic dosage has been found that dose remains unchanged indefinitely while experiencing OFF periods. This study will review patients 12 months after the commencement of apomorphine to determine the on-going effect of the treatment.
Intervention code [1] 333772 0
Treatment: Drugs
Description of the comparator or control
This is an uncontrolled trial. Patients that do not meet the inclusion criteria and/or trigger an exclusion criterion will be offered the treatment using the current recommendations for the initiation of Apomorphine therapy. This includes the need for two electrocardiograms and the commencement of Domperidone, an anti-nausea medication.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345073 0
Patient reported time to achieving ON state at one month posttest dose
Timepoint [1] 345073 0
Week four (primary endpoint) posttest dose and 12 months posttest dose.
Secondary outcome [1] 460355 0
Number of nausea adverse events.
Timepoint [1] 460355 0
Weekly up to one month posttest dose and 12 months posttest dose.
Secondary outcome [2] 460356 0
Global impression of severity
Timepoint [2] 460356 0
Baseline, one month and 12 months posttest dose
Secondary outcome [3] 460357 0
Motor Score
Timepoint [3] 460357 0
Baseline, one month and 12 months posttest dose.
Secondary outcome [4] 460699 0
Global impression of severity
Timepoint [4] 460699 0
Baseline, one month and 12 months posttest dose

Eligibility
Key inclusion criteria
1. Adults with idiopathic PD.
2. Patients on an optimally maximized oral anti-PD medication for at least 30 days.
3. Experience at least one OFF medication period daily that is not amenable to oral therapy changes.
4. No other neurological condition that may affect their ability to follow instructions.
5. Female participants of childbearing potential and male participants with female partners of childbearing potential must agree to either remain abstinent or use highly effective and reliable contraception throughout the study and for at least 12 weeks after the last dose of apomorphine has been taken.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. History of nausea with PD medication and/or a predisposition to nausea and vomiting.
2. Atypical parkinsonism.
3. Known hypersensitivity or allergy to apomorphine, morphine, or other sodium metabisulphites (sulphur).
4. Known neuropsychiatric condition or hallucinations.
5. Diagnosed dementia.
6. Patients with unstable and clinically significant orthostatic hypotension.
7. High risk cardiac history including prolonged QTc and arrhythmias, cardiac decompensation and cerebrovascular disease.
8. Currently lactating or pregnant or planning to become pregnant during the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321611 0
Commercial sector/Industry
Name [1] 321611 0
Project Patron - STADA Pharmaceuticals Australia Pty Ltd
Country [1] 321611 0
Australia
Funding source category [2] 321766 0
Hospital
Name [2] 321766 0
Monash Health
Country [2] 321766 0
Australia
Primary sponsor type
Hospital
Name
Monash Health
Address
Country
Australia
Secondary sponsor category [1] 324421 0
Commercial sector/Industry
Name [1] 324421 0
Project Patron - STADA Pharmaceuticals Australia Pty Ltd
Address [1] 324421 0
Country [1] 324421 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320135 0
Monash Health Human Research Ethics Committee A
Ethics committee address [1] 320135 0
Ethics committee country [1] 320135 0
Australia
Date submitted for ethics approval [1] 320135 0
11/09/2025
Approval date [1] 320135 0
28/04/2026
Ethics approval number [1] 320135 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149554 0
Dr Nirosen Vijiaratnam
Address 149554 0
Monash Health, 400 Warrigal Road, Heatherton, VIC 3202
Country 149554 0
Australia
Phone 149554 0
+61392652177
Fax 149554 0
Email 149554 0
Contact person for public queries
Name 149555 0
Anna Murphy
Address 149555 0
Monash Health, 400 Warrigal Road, Heatherton, VIC 3202
Country 149555 0
Australia
Phone 149555 0
+61392651453
Fax 149555 0
Email 149555 0
Contact person for scientific queries
Name 149556 0
Nirosen Vijiaratnam
Address 149556 0
Monash Health, 400 Warrigal Road, Heatherton, VIC 3202
Country 149556 0
Australia
Phone 149556 0
+61392651453
Fax 149556 0
Email 149556 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.